Last reviewed · How we verify

Tretinoin cream 0.05

Massachusetts General Hospital · FDA-approved active Small molecule

Tretinoin is a vitamin A derivative that binds to retinoic acid receptors in the nucleus, promoting cell differentiation and reducing sebum production and comedone formation.

Tretinoin is a vitamin A derivative that binds to retinoic acid receptors in the nucleus, promoting cell differentiation and reducing sebum production and comedone formation. Used for Acne vulgaris, Photoaged skin and fine wrinkles, Melasma.

At a glance

Generic nameTretinoin cream 0.05
SponsorMassachusetts General Hospital
Drug classRetinoid
TargetRetinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Tretinoin acts as a ligand for nuclear retinoic acid receptors (RAR and RXR), which regulate gene transcription involved in cell proliferation and differentiation. In the skin, it increases cell turnover, normalizes keratinization, and reduces sebaceous gland activity. These effects help unclog pores, reduce inflammation, and improve acne lesions and photoaged skin.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: